If you have been searching for peptide therapy in Miami, you have probably noticed something strange: the same handful of compounds show up on wellness clinic menus, telehealth sites, and Instagram ads, and almost none of those pages explain what is actually approved, what is legally compoundable, and what is being sold in a legal grey zone. That gap matters, because peptides are prescription-grade drugs, not supplements.
This guide is written for the patient who is preparing for a first consultation at a Miami clinic and wants to walk in informed. It covers what peptides are, where U.S. regulation actually stands in 2026, why sourcing is the single largest safety variable, what a responsible screening process looks like, what the evidence genuinely supports, and how follow-up should work. At Nexsis BioHealth in Brickell, this is roughly the same conversation our physicians have with every new patient.
A peptide is a short chain of amino acids — generally fewer than about 50 — held together by peptide bonds. Proteins are longer chains of the same building blocks. Your body already makes thousands of them, and many act as signaling molecules: they bind a receptor and instruct a cell to do something specific, such as release growth hormone, slow gastric emptying, or suppress appetite.
That signaling role is why peptides get marketed as precise. It is a fair description of the mechanism and a poor description of the outcome. A molecule can bind its receptor exactly as designed and still fail to produce a benefit a patient can feel, and still carry side effects. Precision at the receptor is not the same as clinical efficacy.
Peptides discussed in wellness settings fall into a few broad groups:
Those four groups sit in radically different regulatory and evidentiary positions. Treating them as one category called "peptide therapy" is the first mistake most marketing makes.
This is the part worth reading twice, because it changed significantly in the past eighteen months and most clinic pages have not caught up.
A small number of peptides are approved drugs with an FDA-cleared label:
One clarification that catches a lot of patients out: sermorelin is frequently described as "FDA-approved," and that is misleading. Its original approval (Geref) was withdrawn in 2009 when the manufacturer discontinued it. The FDA later confirmed the withdrawal was not for safety or effectiveness reasons, which keeps the door open for generics, but there is no FDA-approved sermorelin product on the U.S. market today. Any sermorelin a clinic offers is a compounded preparation.
Compounding pharmacies operate under two sections of federal law: 503A (patient-specific prescriptions) and 503B (outsourcing facilities). A pharmacy can only compound using a bulk drug substance if that substance sits in an acceptable regulatory category. The FDA sorts nominated substances into Category 1 (may be compounded under enforcement discretion while evaluation continues), Category 2 (may present significant safety risks — do not compound), and Category 3 (insufficient information).
In September 2023, the FDA placed 19 peptides into Category 2, effectively shutting down legal compounding of BPC-157, ipamorelin, CJC-1295, epitalon, TB-500, melanotan II and others.
In April 2026, the FDA removed 12 of those peptides from Category 2 — including BPC-157, TB-500, epitalon, GHK-Cu, KPV, MOTS-c and semax — after the underlying nominations were withdrawn. This generated a wave of "peptides are back" marketing. That marketing is wrong. Removal from Category 2 does not place a substance on the 503A bulks list and does not move it into Category 1. It removes a prohibition without granting a permission. Those compounds now sit in a genuine regulatory limbo.
In late July 2026, the FDA's Pharmacy Compounding Advisory Committee voted in favor of adding six peptides — BPC-157, KPV, TB-500, semax, MOTS-c and epitalon — to the 503A bulks list for specific narrow indications. Several votes were close, and the FDA's own scientific staff recommended against all of them, citing insufficient safety and efficacy data, immunogenicity concerns and inadequate characterization of the substances.
Here is the part that matters for you as a patient: the advisory committee does not make law. The FDA is not bound by its votes, and formal notice-and-comment rulemaking is still required. As of August 2026, none of those six peptides is legally compoundable. Any Miami clinic telling you the July vote made BPC-157 available is either misinformed or hoping you are.
Peptides that remain in Category 2 today are GHRP-2, GHRP-6, ibutamoren, ipamorelin (for 503B facilities) and kisspeptin-10.
During the 2023–2024 shortages, compounded semaglutide and tirzepatide were widely available because federal law permits compounding copies of drugs in shortage. Those shortages were resolved — tirzepatide first declared resolved in October 2024 and reaffirmed that December, semaglutide in February 2025 — and the enforcement discretion windows closed in stages through May 2025.
Routine compounded semaglutide and tirzepatide are no longer permitted. In April 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list entirely, on a finding of no clinical need. If finalized, that would bar outsourcing-facility compounding of these drugs regardless of any future shortage.
Practically: if a Miami provider is still offering cheap compounded semaglutide in 2026, ask them directly to explain the legal basis. Our medical weight loss program uses prescribed, FDA-approved GLP-1 therapy for precisely this reason.
Search data for Miami shows real local demand for phrases like "where to buy peptides in Miami," "peptide shop," and "retatrutide peptide buy." Those searches lead almost exclusively to grey-market vendors, and the risk there is not theoretical.
Grey-market sellers label vials "research use only — not for human consumption" and assume the disclaimer protects them. The FDA has explicitly rejected that position. In a March 2026 warning letter to a California peptide seller marketing retatrutide and tirzepatide, the agency held that the company's own marketing language — appetite suppression, weight management — established intended human drug use regardless of the disclaimer, and noted that injectable products "bypass some of the body's key defenses against toxins." A September 2025 warning letter to an overseas seller of compounded retatrutide, semaglutide and tirzepatide made the same finding.
A 2024 peer-reviewed market surveillance study published in the Journal of Medical Internet Research test-purchased semaglutide from illegal online sellers and analyzed what arrived. The findings:
Endotoxin is not a minor impurity. Contaminated infusion products have produced clusters of acute febrile reactions and hospitalizations. When the injection is going into your bloodstream, sterility and endotoxin testing are the whole ballgame.
Retatrutide is Eli Lilly's triple GIP/GLP-1/glucagon agonist. Its phase 3 TRIUMPH results, reported in July 2026, are genuinely impressive — up to roughly 21% body weight reduction in one trial and 22.6% in another at 80 weeks. Lilly has said it plans to submit for FDA approval in the first quarter of 2027.
It is not approved anywhere as of August 2026. It is not on any bulks list, which means it cannot be legally compounded under either 503A or 503B, and it cannot be legally sold for human use in the United States. Every vial currently being sold online is unapproved, untested and outside the regulatory system. The earliest plausible U.S. approval is 2027 to 2028. A legitimate clinic will tell you to wait.
If a provider cannot answer all four, that is your answer.
Worth saying plainly: there is no professional-society guideline that defines "peptide therapy" baseline labs. What follows is extrapolated from the FDA labels for the approved growth-hormone-axis drugs and from the American Association of Clinical Endocrinology guidance on adult growth hormone deficiency. A clinic that presents its panel as an established standard is overselling. A clinic that can explain where each test comes from is doing it properly.
The first half of a good consultation is conversation, not phlebotomy. What are you actually trying to change — body composition, recovery from training, sleep, energy, a specific injury, metabolic health? How long has it been a problem? What have you already tried? What medications and supplements are you on? What is your cancer screening history, and is it current?
That last question is not a formality. It changes what is safe to offer.
A defensible baseline panel, with the reasoning behind each element:
One important caveat the endocrinology guidance is emphatic about: a random IGF-1 level cannot by itself diagnose adult growth hormone deficiency. Formal stimulation testing is required. If a clinic tells you that a single low-normal IGF-1 means you are "deficient" and need a secretagogue, that is not how the diagnosis works.
For growth-hormone-axis peptides specifically, the approved-drug labels are the best available guide, and they are strict:
Before the first injection, you should know the specific compound, the dose, the schedule, the intended endpoint, how that endpoint will be measured, when it will be reassessed, and the criteria for stopping. "Feeling better in a few weeks" is not an endpoint. Body composition on InBody analysis, a lab value, a validated symptom score or a functional measure is.
This is where an honest clinic separates itself from a dispensary.
Semaglutide and tirzepatide have large, well-conducted randomized trials showing substantial and durable weight reduction, glycemic improvement, and — for semaglutide — cardiovascular risk reduction. This is the best-evidenced corner of peptide medicine by a wide margin, and it is the one where the approved products are readily available.
Two systematic reviews in the Annals of Internal Medicine set the ceiling on expectations. The 2007 review of growth hormone in healthy older adults (18 randomized trials, 508 participants) found lean body mass increased about 2.1 kg and fat mass fell about 2.1 kg — but no significant difference in strength, alongside significantly higher rates of soft tissue edema, carpal tunnel syndrome, arthralgia and gynecomastia. Its conclusion was that growth hormone cannot be recommended as an anti-aging therapy.
The 2008 companion review on athletic performance (27 trials, 440 participants) found the same pattern: lean mass up roughly 2 kg, no statistically significant strength improvement, minimal effect on performance, and soft tissue swelling in 44% versus 1% on placebo.
For ipamorelin and CJC-1295 specifically, there are no published randomized human trials demonstrating clinical benefit for anti-aging, body composition or performance endpoints. The available literature is preclinical and promotional. A two-year randomized trial of the oral secretagogue MK-677 in healthy older adults prompted an accompanying editorial titled "Not Yet Ready for Prime Time" — a fair summary of the whole category.
A 2025 systematic review in the HSS Journal examined BPC-157 in orthopaedic sports medicine and found 36 studies: 35 preclinical animal studies and one clinical study. The evidence was graded at Levels IV and V — the lowest available tiers. The authors stated directly that there is no clinical safety data in humans, and flagged the risk of adverse effects from unregulated manufacturing and contamination.
The animal data are interesting. That is not the same as a reason to inject it.
Realistic timelines depend entirely on which compound and which endpoint. GLP-1 therapy produces measurable appetite change within weeks and meaningful weight change over months, with dose titration throughout. Growth-hormone-axis therapy, where appropriate, is assessed over months using IGF-1 and body composition, not by how you feel on week two.
Follow-up should include repeat IGF-1 for anyone on a growth-hormone-axis agent, with dose reduction or discontinuation for persistent elevation without a corresponding response; periodic glucose and HbA1c given the documented diabetes signal; and a scheduled decision point where you and your physician agree either to continue, adjust, or stop. Therapy that continues indefinitely because nobody scheduled a review is not a protocol.
Stop and call your clinic for new or worsening swelling in the hands and feet, new joint pain or stiffness, numbness or tingling in the hands, unusual fatigue, injection site reactions beyond mild local redness, or any new lump or symptom that would ordinarily prompt cancer screening.
Peptides are rarely a standalone answer. Most patients we see in Brickell are working on some combination of metabolic health, recovery capacity and inflammation, and peptides are one lever among several. Depending on your goals and labs, a physician might pair or sequence therapy with our physician-led medical weight loss program, IV nutrient therapy, hyperbaric oxygen therapy, or red light therapy. Sleep, training load, alcohol and protein intake move most of these endpoints more than any injection does, and a good consultation will say so.
Prescribing an FDA-approved peptide is straightforward and legal. Compounded peptides are legal only where the substance's regulatory status permits compounding and a licensed prescriber has written a patient-specific prescription. Buying peptides online from a vendor with a "research use only" label is outside that system entirely.
Cost varies widely by compound and whether the product is an approved brand drug or a compounded preparation, and insurance generally does not cover wellness-indication use. Ask for the full monthly cost including labs and follow-up visits before you start, not just the price of a vial. We give patients a written cost breakdown at consultation.
Yes. Any clinic willing to inject you without baseline labs and a documented review of your cancer screening history is not screening you — it is dispensing.
Sometimes, but it depends on the specific combination, your glucose status and your nutritional intake. Markedly reduced food intake on a GLP-1 changes how your body handles other interventions, and that interaction needs to be managed by the same physician overseeing both.
For GLP-1 therapy, appetite changes are usually noticeable within the first few weeks. For growth-hormone-axis therapy, meaningful body composition change is measured over three to six months. Anyone promising dramatic results in days is describing a placebo response or a different drug than the one on the label.
Then you have learned something valuable. An active malignancy, an untreated pituitary issue, uncontrolled diabetes or a pregnancy is a genuine reason not to proceed, and there are usually other routes to the same goal. A clinic that finds a way to say yes to everyone is not screening anyone.
Nexsis BioHealth is a physician-led regenerative medicine clinic at 40 SW 13th Street, Suite 601–602 in Brickell, serving patients across Miami, Coral Gables, Coconut Grove, Downtown Miami, Wynwood and Key Biscayne. A peptide consultation begins with a full history and goals review, moves to baseline labs, and ends with a written plan you can read before you commit to anything.
If your consultation concludes that a peptide is not the right tool for your goal, we will tell you that. Book a consultation or call (844) 741-1580.
This article is for general educational purposes and does not constitute medical advice, diagnosis or treatment, and it does not create a physician-patient relationship. Peptides discussed here include compounds that are not approved by the U.S. Food and Drug Administration for the uses described. Regulatory status changes; the information above reflects the position as of August 2026. Do not start, stop or change any therapy without consulting a licensed physician who has reviewed your medical history.
